IRF2

Across TCGA pan-cancer cohorts, IRF2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated IRF2 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher IRF2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated IRF2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, LUAD, and PDAC are the cancer types where IRF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	III,IV	1.000	0.185	.008	29	view →
LUAD	DFS	Tertile	All	0.898	0.668	.003	22	view →
PDAC	DFS	Quartile	All	0.506	0.251	.001	20	view →
CCRCC	DFS	Quartile	II,III,IV	1.000	0.347	.016	7	view →
OV	DFS	Median	All	0.520	0.913	.033	4	view →
GBM	DFS	Median	All	0.335	0.203	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

IRF2–HNSC (DFS)

Open the HNSC breakdown →